Greenman J - Search Results

1

Oligoubiquitination of tissue factor on Lys255 promotes Ser253-dephosphorylation and terminates TF release.

Ettelaie C, Collier ME, Featherby S, Greenman J, Maraveyas A. Ettelaie C, et al. Among authors: greenman j. Biochim Biophys Acta. 2016 Nov;1863(11):2846-2857. doi: 10.1016/j.bbamcr.2016.09.005. Epub 2016 Sep 4. Biochim Biophys Acta. 2016. PMID: 27599717 Free article.

2

Heat shock proteins in vascular disease--a review.

Mehta TA, Greenman J, Ettelaie C, Venkatasubramaniam A, Chetter IC, McCollum PT. Mehta TA, et al. Among authors: greenman j. Eur J Vasc Endovasc Surg. 2005 Apr;29(4):395-402. doi: 10.1016/j.ejvs.2005.01.005. Eur J Vasc Endovasc Surg. 2005. PMID: 15749041 Free article. Review.

3

From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials.

Lam T, Hetherington JW, Greenman J, Maraveyas A. Lam T, et al. Among authors: greenman j. Anticancer Drugs. 2006 Feb;17(2):113-21. doi: 10.1097/00001813-200602000-00001. Anticancer Drugs. 2006. PMID: 16428928 Review.

4

Tumour-expressed tissue factor inhibits cellular cytotoxicity.

Li C, Colman LM, Collier ME, Dyer CE, Greenman J, Ettelaie C. Li C, et al. Among authors: greenman j. Cancer Immunol Immunother. 2006 Nov;55(11):1301-8. doi: 10.1007/s00262-006-0130-1. Epub 2006 Feb 2. Cancer Immunol Immunother. 2006. PMID: 16453151

5

Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth.

Lam T, Hetherington JW, Greenman J, Little S, Maraveyas A. Lam T, et al. Among authors: greenman j. Acta Oncol. 2007;46(8):1169-77. doi: 10.1080/02841860701373603. Acta Oncol. 2007. PMID: 17851838

6

Investigation of the mechanisms of tissue factor-mediated evasion of tumour cells from cellular cytotoxicity.

Li C, Collier ME, Frentzou GA, Greenman J, Ettelaie C. Li C, et al. Among authors: greenman j. Cancer Immunol Immunother. 2008 Sep;57(9):1347-55. doi: 10.1007/s00262-008-0469-6. Epub 2008 Feb 23. Cancer Immunol Immunother. 2008. PMID: 18297283

7

Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion.

Maraveyas A, Ettelaie C, Echrish H, Li C, Gardiner E, Greenman J, Madden LA. Maraveyas A, et al. Among authors: greenman j. Blood Coagul Fibrinolysis. 2010 Jul;21(5):452-8. doi: 10.1097/MBC.0b013e328338dc49. Blood Coagul Fibrinolysis. 2010. PMID: 20386431 Clinical Trial.

8

Pancreatic cancer cell and microparticle procoagulant surface characterization: involvement of membrane-expressed tissue factor, phosphatidylserine and phosphatidylethanolamine.

Yates KR, Welsh J, Echrish HH, Greenman J, Maraveyas A, Madden LA. Yates KR, et al. Among authors: greenman j. Blood Coagul Fibrinolysis. 2011 Dec;22(8):680-7. doi: 10.1097/MBC.0b013e32834ad7bc. Blood Coagul Fibrinolysis. 2011. PMID: 21941170

9

Tissue factor expression determines tumour cell coagulation kinetics.

Welsh J, Smith JD, Yates KR, Greenman J, Maraveyas A, Madden LA. Welsh J, et al. Among authors: greenman j. Int J Lab Hematol. 2012 Aug;34(4):396-402. doi: 10.1111/j.1751-553X.2012.01409.x. Epub 2012 Feb 20. Int J Lab Hematol. 2012. PMID: 22348286

10

Duramycin exhibits antiproliferative properties and induces apoptosis in tumour cells.

Yates KR, Welsh J, Udegbunam NO, Greenman J, Maraveyas A, Madden LA. Yates KR, et al. Among authors: greenman j. Blood Coagul Fibrinolysis. 2012 Jul;23(5):396-401. doi: 10.1097/MBC.0b013e3283538875. Blood Coagul Fibrinolysis. 2012. PMID: 22543977

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

394 results

Search Page